This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
by Dennis Crouch The Supreme Court is set to consider several significant patentlaw petitions addressing a range of issues from the application of obviousness standards, challenges to PTAB procedures, interpretation of joinder time limits IPR, to the proper scope patent eligibility doctrine. 1, at 48 (2011). 112–98, pt.
So these studies can’t tell us much about what’s going on in the Federal Circuit era, unless one assumes—unreasonably—that the Federal Circuit didn’t meaningfully change design patentlaw. We also looked at design patent outcomes in the International Trade Commission and the UPSTO Patent Trial and Appeal Board.
In order to facilitate resolution of brand-generic patent conflict, the PatentLaws include a form of paper infringement–a legal fiction that simply filing an ANDA and Paragraph IV certification counts as a form of patentinfringement. ” In re Brimonidine Patent Litig.,
On June 1, 2021, the Fourth Amendment to the Chinese PatentLaw became effective. An important part of the amendment is the introduction by Article 76 of the patent linkage system in China – a system for litigation of drug patents prior to market entry of generics, similar to that provided by the Hatch Waxman Act in the US.
We’re pleased to bring to you a guest post by Eashan Ghosh on the treatment of prosecution history in trade mark infringement proceedings. Eashan has been practicing as an intellectual property advocate and consultant in New Delhi since 2011, and teaches a seminar on intellectual property law at National Law University, Delhi.
Campbell filed a provisional application in 2011 and a non-provisional in 2012 that eventually issued in 2016. The Patent Act includes a 6-year statute of limitations, but as written it only applies to cut-off recovery for patentinfringement — and does not apply to lawsuits to correct inventorship. 663 (2014).
Breadth of the Covenant : The Federal Circuit held that the plain language of the covenant not to sue in the License Agreement between AlexSam and MasterCard was extremely broad, covering not just potential patentinfringement suits but also AlexSam’s breach of contract suit to recover unpaid royalties under the Agreement.
By Dennis Crouch In 1931, the United States Supreme Court decided a landmark case on the patentability of inventions, De Forest Radio Co. The case involved a patentinfringement suit over an improved vacuum tube used in radio communications. Background The patent at issue, U.S. 57, 111 (2011). 571 (1931).
On June 1, 2021, the Fourth Amendment to the Chinese PatentLaw became effective. An important part of the amendment is the introduction by Article 76 of the patent linkage system in China – a system for litigation of drug patents prior to market entry of generics, similar to that provided by the Hatch Waxman Act in the US.
and the wealthy countries, Moderna announced that it expected its competitors to respect Moderna’s intellectual property and that it would offer patent licenses on reasonable terms to those who asked. On August 26, 2022, Moderna sued Pfizer and BioNTech for patentinfringement in the district court in Massachusetts.
Kessler Doctrine is particular to patentlaw and falls somewhere in-between issue and claim preclusion–allowing preclusion in instances where it would not be traditionally available. Here, PersonalWeb sued Amazon for patentinfringement back in 2011 based upon Amazon’s use of its S3 cloud storage services.
We organize all of the trending information in your field so you don't have to. Join 9,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content